Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a reduced net loss of $1.14 per share in 2Q25, which was better than analysts' initial estimate of $1.22 per share, indicating improved financial performance. The clinical trial results for OKI-219 showed that the treatment was well-tolerated, with no reports of hyperglycemia and only Grade 1 treatment-related adverse events, signifying a favorable safety profile. This combination of narrowing losses and positive clinical outcomes enhances OnKure’s potential for future growth and strengthens its position in the clinical biopharmaceutical market.

Bears say

OnKure Therapeutics Inc. faces a projected full-year net loss of $4.56 per share for 2025, indicating a worsening financial outlook from the previous estimate of $4.75 per share. The company is exposed to significant risks, including potential negative clinical results for its lead asset, OKI-219, and delays in advancing pipeline candidates, which could hinder future growth and revenue generation. Additionally, challenges in obtaining timely regulatory approvals and competition from other mutant-selective PI3Kα inhibitors further exacerbate concerns about the company's long-term viability and potential dilution risk for shareholders.

OKUR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 2 analysts, OKUR has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.